Phathom Gets Expanded FDA OK of Voquezna in Non-Erosive GERD

By Colin Kellaher

Phathom Pharmaceuticals has received the Food and Drug Administration's expanded approval of its acid-reflux drug Voquezna for the most common form of gastroesophageal reflux disease, or GERD.

Phathom on Thursday said the approval covers Voquezna for the relief of heartburn associated with non-erosive GERD in adults.

The Florham Park, N.J., biopharmaceutical company said about 45 million American adults suffer from non-erosive GERD, which is characterized by typical GERD symptoms such as heartburn and regurgitation but without esophageal erosion, with roughly 15 million treated with a prescription medicine annually.

The FDA late last year approved Voquezna to treat all severities of erosive esophagitis, also known as erosive GERD, and in combination with antibiotics for the eradication of Helicobacter pylori infection.

Shares of Phathom, which closed Wednesday at $12.11, were recently up 5% at $12.72 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 18, 2024 08:42 ET (12:42 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.